Brain training app shows promise for mild cognitive impairment
NCT ID NCT06264557
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a cognitive training software called SUPERBRAIN DEX in 140 people aged 50–85 with mild cognitive impairment (MCI), a condition that can lead to dementia. Participants used the software for 15–30 minutes daily, while a control group received an educational booklet on dementia prevention. The goal was to see if the software could improve memory and thinking better than simple education. The trial is now complete, and results will show whether this digital approach can help slow cognitive decline.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- SUPERBRAIN DEX cognitive training software
- What this could lead to
- If it works, this software could offer a safe, drug-free way to help people with mild cognitive impairment maintain or improve their memory and thinking skills.
- What could go wrong
- This is a small, completed trial with 140 participants. The results may not apply to everyone, and the improvement might be modest. There is no guarantee the software will outperform simple education.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
140 people
The number who actually took part.
- Started
-
Jan 2024
- Finished
-
Jun 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. 50 - 85years old 2. Those who meet all of the National Institute on Aging-Alzheimer's Association (NIA-AA) key clinical criteria below that may suspect mild cognitive impairment caused by Alzheimer's disease as of the screening date * Concern of the subject or guardian about the deterioration of cognitive function compared to before * More than one cognitive impairment * Maintaining the independence of overall daily life functions * It's not dementia 3. In at least one of the following neuropsychological tests conducted within one year of the screening date, the delayed recall score in the memory area was 'average -1' according to the standard score table corrected for education level and age. * Seoul Neuropsychological Screening Battery 2nd edition (SNSB-II) * Korean version of Consortium to Establish a Registry for Alzheimer's Disease (CERAD-K) * Literacy Independent Cognitive Assessment (LICA) 4. A person whose Korea-Mini Mental State Examination-2 (K-MMSE-2) score corresponds to "Average-1.5 standard deviation or higher" according to the standard score table corrected for education level and age as of the screening date 5. Those with a Global Clinical Dementia Rating (CDR) score of 0.5 and a memory item score of 0.5 or 1 as of the screening date 6. A person who has a guardian in regular contact with the subject * Defined to be able to support subjects during the clinical trial (compliance supervision and subject status reporting) and spend at least 8 hours per week with subjects 7. A person who is taking drugs (donepezil, galantamine, ribastigmine, memantine) for the purpose of improving cognitive function is taking drugs stably for at least 12 weeks as of the screening date 8. Those who have no difficulty using tablet PCs 9. A person who voluntarily decides to participate in this clinical trial and agrees to the subject's explanation and consent in writing 10. Those who are willing to comply with the clinical trial plan Exclusion Criteria: 1. Those diagnosed with dementia (including Alzheimer's disease, vascular dementia, infections of the central nervous system (e.g., Human Immunodeficiency Virus (HIV), syphilis, etc.), Creutzfeld-Jacob disease (Creutzfeld-Jacob disease), Pick disease, Huntington's disease, Parkinson's disease, etc.) as of the screening date 2. Those who have a history of diagnosing significant neurological diseases affecting cognitive function within one year of the screening date (e.g., stroke, multiple sclerosis, severe head trauma with loss of consciousness, normal cerebral hydrocephalus, epilepsy, brain tumors, cerebral infarction, spinal cord infarction or central nervous system infection) 3. Based on the screening date, major depressive disorder, bipolar disorder, schizophrenia, A person diagnosed with a serious mental illness such as drug addiction and alcoholism 4. Laboratory and/or vital signs tests as of the date of screening, any of the following * Those diagnosed with infectious or metabolic diseases that may cause cognitive decline in the subject (e.g., hypothyroidism, vitamin B12 deficiency, folate deficiency, neurotoxin, HIV) * Those with liver dysfunction (AST, ALT ≥ 3x upper limit of normal range) and/or renal dysfunction (serum creatinine ≥ 2x upper limit of normal range) * Those with uncontrolled hypertension (SBP \> 180 mmHg) and/or diabetes (HbA1c \> 11%) 5. Those who have severe or unstable cardiovascular disease (e.g., myocardial infarction, unstable angina, class III or IV heart failure by classification of the New York Heart Association (NYHA) within 24 weeks of the screening date) 6. Where the tester determines that he/she has a medical condition that may interfere with the completion of the clinical trial due to a serious or unstable physical condition (e.g., a history of malignant tumors within five years of the screening date (e.g., basal cell cancer and squamous cell carcinoma of the skin considered to have been completely resected and cured, cervical intraepithelial carcinoma, non-transparent prostate cancer, acute and severe asthma, active peptic ulcers, etc.) 7. If you can't walk, A person who can move using walking aids (e.g. walkers, canes, wheelchairs, etc.) 8. an illiterate patient who is unschooled (defined as unadmitted to a regular school) 9. Where the tester determines that a person does not have sufficient vision, hearing, language skills, motor skills, and comprehension to follow the examination procedures related to clinical trials 10. a person who is pregnant or nursing 11. For women of childbearing age, who do not agree with the medically permitted contraceptive method during the clinical trial * Hormonal contraception, intrauterine device (IUD) or intrauterine system (IUS), oviduct ligation, double blocking (male condom, female condom, cervical cap, a combination of contraceptive septum, contraceptive sponge-like blocking methods), a single blocking method with a combination of an alveolar agent 12. Those who are currently participating in other clinical trials or who have participated in other clinical trials within 90 days of screening 13. Other, ethical or clinical trial outcomes may be impacted and deemed inappropriate by the tester
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCI are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ajou University Hospital
Suwon, South Korea
-
Chonnam National University Hospital
Kwangju, South Korea
-
Ewha Womans University Seoul Hospital
Seoul, South Korea
-
Gachon University Gil Medical Center
Incheon, South Korea
-
Hanyang University Guri Hospital
Guri-si, Gyeonggi-do, 11923, South Korea
-
Hanyang University Seoul Hospital
Seoul, South Korea
-
Inha University Hospital
Incheon, 22332, South Korea
-
Inje University Haeundae Paik Hospital
Busan, South Korea
-
Koera University Guro Hospital
Seoul, South Korea
-
Korea University Anam Hospital
Seoul, South Korea
-
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea
-
The Catholic University of Korea, St. Vincent's Hospital
Suwon, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Walking memory tests may reveal early Parkinson's clues
- Can tango rewire the brain? dance program tested for Parkinson's and dementia
- Can tiny bursts of baduanjin exercise sharpen a fading memory?
- Can pool workouts plus brain games sharpen memory in aging veterans?
- Can home exercise keep older adults with cognitive frailty on their feet?
- A new brain scan tracer aims to light up myelin damage